Optimizing Surrogate Matrix Selection for Endogenous Biomarker LC-MS/MS Quantitation Assays

Nicole B. Gonzalez Salguero[1], Benjamin Begley[1], Simon Johnson[1], Theron Chung[1], Davonne Auguste[1], John Begley[1], Shane Karnik[1] [1]Aliri Bioanalysis

Introduction

Historically, LC-MS/MS focused on synthetic drug pharmacokinetics. However, improved sensitivity now allows the analysis of endogenous biomarkers (lipids, proteins, etc.) previously reserved for Ligand Binding Assays (LBA). A primary challenge in biomarker bioanalysis is that these compounds are endogenous to biological matrices, and the matrix could present challenging physicochemical properties. Unlike conventional drug testing, there is no true blank matrix available to build calibration standards. To quantify these levels accurately, researchers must develop a surrogate matrix that mimics the behavior of authentic patient samples without the background interference of the natural analyte. Selecting and validating this surrogate is the most critical step in establishing a reliable LC-MS/MS method for any naturally occurring compound.



Method

For the small molecule biomarker, five different commercially available artificial matrices and two in-house BSA/HSA solutions were screened: Serasub (Technologies, Inc.),UTAK SMx Serum (Invicon), Simulated Blood Serum (Biochemazone), Artificial Serum Xeno-free (Diagnocine), and SigMatrix Ultra Serum Diluent (Sigma). Calibrants (2.5–1,000 ng/mL) and QCs were compared between surrogate and native human serum using LC-MS/MS. Effective extraction required biliverdin depletion from simulated blood serum (Biochemazone), followed by acidic protein precipitation. Extracts were then analyzed with a Shimadzu LC-30 AD coupled with a Sciex Triple Quad 6500 ESI MS.

For the protein analysis, recombinant protein calibrants (0.5–100 ng/mL) were prepared in surrogates with controlled BSA titration (3.5–52.5 mg/mL). Human adipose tissue was homogenized, filtered to remove fat, and analyzed.
Extraction involved immunoprecipitation followed by tryptic digestion. A Shimadzu LC-30 AD coupled with a Sciex Triple Quad 7500 ESI MS was used for sample analysis.
Parallelism was assessed to ensure surrogate matrices accurately mirrored native matrix behavior.

Results

We assessed the quantitation of biliverdin (~582 Da)-commonly used as an indicator of vascular stability. Endogenous levels determination proved challenging due to biliverdin's presence in all commercial plasma simulators. SigMatrix (containing 0.3% Triton X-100) showed successful parallelism with native serum. However, due to procurement difficulties, we developed a more accessible alternative: using a 10 kDa molecular weight cut-off (MWCO) filter. This method successfully maintained background concentrations below 20% of the LLOQ, ensuring a robust, native-like surrogate matrix for accurate calibration.

We extended our rationale to a >50 kDa protein biomarker in human adipose tissue. Since tissue matrices are rare and cannot be replaced by standard serum surrogates, we artificially varied the protein concentration by titrating Bovine Serum Albumin (BSA) into a saline buffer to match the average protein density of native human fat. High lipid content was found to interfere with protein recovery and created significant matrix effects. To resolve this, we incorporated a delipidation step after homogenization. By matching the protein concentration and removing interfering fats, we achieved responses in our surrogate matrix that were comparable to native tissue.

Conclusions

We have established scalable workflows for matrix selection across bioanalytical assays for both small and large molecule biomarkers. These strategies are utilized for routine sample analysis and assay validation in strict adherence to regulatory guidelines. Our findings highlight that matching protein density and physico-chemical characteristics, alongside interference removal, are essential for achieving accurate quantitation when utilizing surrogate matrices.

Surrogate Matrix Performance for Small Molecule Biomarker



D

Quality Control Sample	% Accuracy Across Replicates				%CV
Surrogate Low QC	99.60	96.90	98.30	87.70	5.64
Surrogate Mid QC	102.00	102.00	100.00	89.70	5.99
Surrogate High QC	111.00	96.90	94.20	101.00	7.31
Native Low QC	95.10	96.60	91.10	91.40	2.92
Native Mid QC	98.10	91.70	89.50	104.00	6.84
Native High QC	86.40	89.10	101.00	108.00	10.55
Endogenous Native QC	105.00	91.20	94.90	——	7.36
Endogenous Native QC (2X dilution)	86.20	88.50	88.90	95.20	4.30
Endogenous Native QC (10X dilution)	83.80	115.00	121.00	106.00	15.32

(A) Representative Calibration Curve prepared in optimized surrogate matrix. **(B-C)** Calculated (%) accuracies for quality control (QC) samples. **(D)** Representative Sample Chromatograms

Surrogate Matrix Performance for Large Molecule Biomarker



(A) Calculated (%) accuracies for quality control (QC) samples prepared in surrogate matrix and native tissue. **(B)** Calculated Protein Concentration (1.5 ng/mL) comparison **(C)** Area Ratio of samples prepared in varying BSA concentrations. **(D)** Representative Calibration Curve prepared in optimized surrogate matrix **(E)** Representative Internal Standard (IS) plot